"Growing is never-ending. As long as you keep learning & evolving you will never stop growing!" #ctDNA #CTCs #LiquidBiopsy Carolina Reduzzi Jeannine Licolli Donahue (Alvim) Eleonora Nicolò Letizia Pontolillo Nadia Bayou Laura Sofia Munoz Arcos Massimo Cristofanilli, MD, FACP Weill Cornell Breast Center WCM Englander Institute for Precision Medicine

The landscape of targeted therapies in HR+ MBC is expanding with more opportunities for patients. Treatment selection now will be based on molecular and safety profile. #mbc International Society of Liquid Biopsy Weill Cornell Medicine Meyer Cancer Center Weill Cornell Medicine Cristofanilli CTC Laboratory #ctdna

#ISLB23 Annual Congress: Sneak Preview! Panel Discussion #2 of multidisciplinary stakeholder workshop on drug & biomarker development, consisting of reps from academics, regulatory bodies, patient advocates, Pharma and Biomarker. Goal: to reach consensus

#ISLB23 It was an amazing Meeting for several reasons: the 400 worldwide participants 34 countries 🌍the 55 international speakers, 115 abstracts of high quality, the discussions but the best the engagement & great atmosphere. We are a big family! Looking forward to #ISLB24 !

Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? - ScienceDirect ⁦WCM Englander Institute for Precision Medicine⁩ ⁦Weill Cornell Medicine Meyer Cancer Center⁩ ⁦Cristofanilli CTC Laboratory⁩ ⁦International Society of Liquid Biopsy⁩ sciencedirect.com/science/articl…

The WCM Englander Institute for Precision Medicine Scientific Director Dr. Massimo Cristofanilli (Massimo Cristofanilli, MD, FACP) will present a Weill Cornell Medicine Physician Scientist Seminar Series lecture, "Liquid biopsy in #breastcancer: Can we use the patient as a new translational model?" Wednesday at noon via Zoom.

Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial academic.oup.com/oncolo/article… Cristofanilli CTC Laboratory WCM Englander Institute for Precision Medicine WCM Englander Institute for Precision Medicine #MBC

Please join us to celebrate 20 years of liquid biopsy history: research, clinical applications and change in practice. WCM Englander Institute for Precision Medicine Massimo Cristofanilli, MD, FACP Weill Cornell Medicine Meyer Cancer Center Cristofanilli CTC Laboratory Christian Rolfo M JOSE SERRANO (LB&Cancer Interception group)

Dr. Eleni Andreopoulou (Eleni Andreopoulou, MD) spoke with Greek news outlet mononewsgr about #BreastCancer #research, treatment, screening, the aims of #PrecisionMedicine, and her personal perspective as a female physician: bit.ly/4bAZOAg (cc: WCM Englander Institute for Precision Medicine)

🚨🔔ISLB 2024 - Save The Date! 23-25 November 2024 in Denver Colorado!. 🏔️🌆Subscribe for the newsletter and prepare your abstracts!! ⁦M JOSE SERRANO (LB&Cancer Interception group)⁩ ⁦Umberto Malapelle⁩ ⁦David Gandara⁩ ⁦Massimo Cristofanilli, MD, FACP⁩ ⁦ELO⁩ ⁦ 2024.islb.info

Our next #PrecisionMedicine Research Conference, "Discussion of Clinical #WGS and Research Whole Exome and #RNASeq," will be presented by Dr. Daniela Guevara, Fellow in Medicine WCM Englander Institute for Precision Medicine, with patients referred by Cora Sternberg and Massimo Cristofanilli, MD, FACP! Feb. 22 at 1 PM via Zoom

Perfect timing for the study to be published NEJM. #ctDNA🩸blood test for screening for colorectal cancer ✔️83% sensitivity ✔️90% specificity March is #ColorectalCancerAwarenessMonth 🩸is more practical 🆚 colonoscopy or 💩 test. Unmet need. OncoAlert nejm.org/doi/full/10.10…

That’s a wrap! It’s been an inspiring time at Focus on TOP #FTOP24! Thanks to our amazing faculty and to everyone who joined us, see you next year! Fabio Puglisi Massimo Cristofanilli, MD, FACP Umberto Malapelle Maria Vittoria Dieci Luca Malorni Gustavo Baldassarre Rossana Roncato Marzia Del Re, PharmD, PhD #Oncology #liquidbiopsy

Time to expand subtype molecular classification incorporating ctDNA #ASCO24 Cristofanilli CTC Laboratory International Society of Liquid Biopsy WCM Englander Institute for Precision Medicine Weill Cornell Medicine Meyer Cancer Center

A novel #ClincialTrial open to enrollment Weill Cornell Medicine NewYork-Presbyterian is evaluating a PARP inhibitor for #BreastCancer patients with somatic BRCA1/2 mutations. Dr. Massimo Cristofanilli (Massimo Cristofanilli, MD, FACP) explains this #research: bit.ly/3yEU7lQ #ASCO24

Important study highlighting the inequity in targeted therapy treatment for MBC. Aside from treatment, do we know the magnitude of inequity in access to molecular testing? How to reduce the inequity in the continuum of care to improve outcome? WCM Englander Institute for Precision Medicine International Society of Liquid Biopsy

Dr. Massimo Cristofanilli (Massimo Cristofanilli, MD, FACP) was involved with a large retrospective #research study shared at #ASCO24 looking at differences in the use of targeted therapies amongst different ethnicities: bit.ly/4dTBhYx

Questions raised by some of these studies, what is the appropriate control arm in unselected population? Should we still design such studies without a molecular selection, stratification or treatment selection? WCM Englander Institute for Precision Medicine Cristofanilli CTC Laboratory

Excellent paper using CTCs and ctDNA in EBC. International Society of Liquid Biopsy Cristofanilli CTC Laboratory WCM Englander Institute for Precision Medicine Carolina Reduzzi Eleonora Nicolò Lorenzo Gerratana